Progeria, also known as HGPS (Hutchinson-Gilford progeria syndrome), is a rare fatal genetic disease characterized by an appearance of accelerated aging in children. This syndrome is typically caused by mutations in codon 608 (C1804T) of the gene encoding lamins A and C, LMNA, leading to the production of a truncated form of the protein called progerin. Owing to their unique potential to self-renew and to differentiate into any cell types of the organism, pluripotent stem cells offer a unique tool to study molecular and cellular mechanisms related to this global and systemic disease. Recent studies have exploited this potential by generating human induced pluripotent stem cells from HGPS patients' fibroblasts displaying several phenotypic defects characteristic of HGPS such as nuclear abnormalities, progerin expression, altered DNA-repair mechanisms and premature senescence. Altogether, these findings provide new insights on the use of pluripotent stem cells for pathological modelling and may open original therapeutic perspectives for diseases that lack pre-clinical in vitro human models, such as HGPS.
or stroke. To date, two new treatment strategies are in clinical trials after showing a restoration of several cellular defects observed in HGPS patient cells and model systems, FTIs (farnesyltransferase inhibitors) and the combination of zoledronate and pravastatin (named ZoPra). The first class of compounds were first described as anticancer agents [12] and recently transposed to progeria after the discovery of the molecular mechanisms leading to progerin accumulation. In 2005, Fong and colleagues assessed the therapeutic interest of FTIs for progeria by demonstrating their capacity to inhibit the prenylation of prelamin A and thus preventing progerin synthesis [13] . Over the last 5 years, several studies have investigated the in vitro and in vivo therapeutic potential of these drugs. Thus it was found that FTIs could inhibit prelamin A prenylation in a dosedependent manner in progerin-overexpressing fibroblasts [14] , decrease cytoplasmic aggregates and restore the mobility of the protein in progerin-transfected HeLa cells [4] , restore normal nuclear morphology [15] and improve DNA repair in HGPS fibroblasts [16] . In vivo studies were performed on several progeria-like mouse models, suggesting that FTIs could reduce the cardiovascular [17] and osteoarticular [18] phenotypes of HGPS. In 2008, a second therapeutic strategy was proposed based on the combination of a statin (pravastatin) and an amino-bisphosphonate (zoledronate), both of which act on the same cholesterol pathway as FTIs [19] . In vitro and in vivo functional improvement with this combined treatment was demonstrated as well as an effect on nuclear abnormalities of primary fibroblasts from patients and on extending lifespan in progeroid Zmpste24 − / − (zinc metalloprotease Ste24 homologue) mice. In addition to acting on the inhibition of the progerin farnesylation, Together, these defects lead to DNA damage, disorganized heterochromatin, genomic instability, altered gene-expression profiles and premature senescence. (B) HGPS children display symptoms related to a global premature aging phenotype such as loss of body fat, scleroderma, alopecia and kidney failure. Moreover, they present baldness, swollen veins and have a beak-shaped nose, two typical features of this syndrome. HGPS patients suffer from atherosclerosis, osteoporosis, premature cardiovascular disease and growth delay.
ZoPra has the advantage of inducing pleiotropic effects which might contribute to improvement of the cardiovascular and osteoporotic phenotypes in HGPS patients [20] . These compounds are currently being explored in clinical trials. More recently, the use of rapamycin, an immunosuppressive and anti-neoplasic drug targeting mTOR (mammalian target of rapamycin) has been investigated to treat HGPS patients. Previously, rapamycin has been described to extend median and maximal lifespan of mice [21] . On the basis of in vitro functional experiments, mainly performed on HGPS patient fibroblasts, it has been described that rapamycin could abolished nuclear blebbing, delay the onset of cellular senescence and enhance the degradation of progerin in HGPS cells [22] . Even though all of these compounds bring new hopes for a potential treatment for HGPS patients, the establishment of in vitro alternative models compatible with high-throughput studies are required to find new classes of compounds.
In vitro HGPS pathological modelling using iPSCs (induced pluripotent stem cells)
Over the last 10 years, most of the information concerning the physiopathology of the disease has been obtained through establishment of HGPS primary skin cell cultures [23] , lamin A-overexpression models [24] or the generation of various mouse models recapitulating part of the disease [25] . However, little is known about cellular and molecular mechanisms of this disease because of the absence of suitable human in vitro models of HGPS. Access to relevant biological material is indeed very difficult because patients are fragile and young, and because of the rarity of the disease which affects less than 200 patients worldwide. Recently, two groups have addressed this challenge by taking advantage of new technology enabling the generation of iPSCs [26] [27] [28] .
Pluripotent stem cell research has significantly changed our perspectives by providing the scientific community with a unique tool for the derivation of disease-specific stem cells. Thanks to their properties of pluripotency and selfrenewal, human pluripotent stem cells can differentiate into any cell type, making them a potential unlimited biological resource. In 1998, Thomson et al. [29] derived the first hESC (human embryonic stem cell) lines providing immediately an attractive model for pathological modelling of human diseases [29] . PGD (pre-implantation genetic diagnosis) gave researchers the possibility of prospectively identifying embryos with specific genetic disorders and then deriving 'disease-specific' hESCs for cystic fibrosis [30] , Huntington's disease [31] , fragile X mental retardation syndrome [32] or, more recently, myotonic dystrophy [33] . In 2007, the generation of hiPSCs (human iPSCs) by Shinya Yamanaka and colleagues broadened this potential to other diseases in which PGD was not available [34] . This pioneering study described the establishment of pluripotent stem cells from somatic cells through the overexpression of four factors: OCT4, SOX2, KLF4 and c-Myc. Subsequently, hundreds of studies have demonstrated that hiPSCs present capacities close to hESCs in terms of self-renewal and pluripotency, offering an alternative unlimited source of cells suitable for pathological modelling, cell therapy or drug discovery (Figure 2) . Such models have already permitted the elucidation of molecular mechanisms of several diseases [35] such as sickle cell anaemia [36] , Parkinson's disease [37] , amyotrophic lateral sclerosis [38] or spinal muscular atrophy [39] . In 2011, hiPSC lines have been derived from HGPS patient fibroblasts, opening new perspectives for progeria research. A first interesting observation has been the absence of either lamin A/C or progerin expression in the undifferentiated hiPSC colonies following the reprogramming process [26] [27] [28] . These data have confirmed the absence of synthesis of Figure 2 In vitro pathological modelling of HGPS using iPSCs iPSCs can be generated by reprogramming of HGPS-affected children's skin fibroblasts with transcription factors (OCT4, SOX2, c-Myc, KLF4) (1). Their two distinctive properties (unlimited self-renewal capacity at the undifferentiated state and differentiation potential) allowed differentiation into several cell types, providing an unlimited biological resource of HGPS cells (2) . These cells constitute a unique tool to study the physiopathology of the disease (3) and to assess the therapeutic potential of new compounds (5) identified via HTS of chemical drugs (4) . Moreover, HGPS-differentiated cell defects can be genetically corrected (6) with the perspective of autologous cell therapy (7). HDAdVs, helper-dependent adenoviral vectors.
those proteins during embryonic development, accounting for the absence of a phenotype during the early developmental period in HGPS patients [11] . Upon the differentiation of HGPS-derived hiPSC progenies, the premature senescence phenotypes and nuclear blebbing appeared, according to the tissue specificity of the syndrome [26] [27] [28] 40] . Six kinds of differentiation have been studied, showing different degrees of abnormalities in fibroblasts, MSCs (mesenchymal stem cells), endothelial cells, SMCs (smooth muscle cells) and VSMCs (vascular smooth muscle cells) but no abnormalities in neural progenitors [28] . Colman and colleagues showed that neural progenitors did not express lamin A/C and did not display any pathological phenotype [28] , suggesting a correlation between the lack of a cognitive defect in HGPS and the tissue-specific expression of lamins in neural cells [41] . Studies were mainly focused on MSCs and VSMCs showing various cell defects: nuclear dysmorphology, cell growth retardation, susceptibility to apoptosis, proliferation reduction, DNA-repair defects, mislocalization of the protein LAP2 (lamin-associated polypeptide 2) and reduced telomere length. Moreover, this model opened the door to the identification of a novel senescence marker by Liu et al. [26] , who demonstrated a deficiency of DNA-PKcs (DNAdependent protein kinase catalytic subunit)/Ku70/Ku80.
Beyond the understanding of the physiopathological features of the disease, this pathological model is also a tool of choice for the identification of new therapeutics.
New therapeutic challenges of progeria syndrome
Thanks to their pluripotency capacities, hiPSCs can selfrenew indefinitely in vitro while maintaining the ability to differentiate into advanced derivatives of all three germ layers. This feature could be harnessed for pharmacological and toxicological testing and as a gene therapy target. Development of targeted gene editing technologies in hiPSCs and hESCs offers new potentials for the efficient treatment of many human diseases. In 2007, Hanna et al. [36] addressed this issue by validating the use of a targeted gene-correction approach in a mouse model of sickle cell anaemia. Once generated, hiPSCs were differentiated into haemopoietic progenitors and subsequently transplanted into irradiated animals, thus partially rescuing the disease phenotype. The same strategy has been recently transposed to humans by generating hiPSCs from genetically corrected fibroblasts derived from patients with Fanconi's anaemia. In this model, genetic correction also resulted in an alleviated phenotype in haemopoietic cells. This year, a breakthrough study by Liu et al. [27] combined the generation of hiPSCs from HGPS patients with a genetic correction by homologous recombination of lamin A mutations. Using HDAdVs (helper-dependent adenoviral vectors), the authors demonstrated a highly efficient method for correcting the causal mutation in hiPSCs and demonstrated the abrogation of progerin expression in fibroblasts derived from hiPSCs and in MSCs in association with their rescue in terms of nuclear architecture and cell senescence. The methodology used in this pioneering study addressed some major issues related to off-target effects of the genetic manipulation by showing the absence of additional mutations or chromosomal aberrations in modified cells. The hiPSC technology thus potentially provides experimental therapists with an unlimited source of genetically corrected cells. Some issues have, however, emerged recently. Over the last few months, a slew of papers have described numerous epigenetic errors and genomic instabilities consequent to the cellular reprogramming itself (reviewed in [42] ). Several alternative strategies are currently under investigation to avoid the random integration of transgenes by using non-integrating viral approaches [43] , small molecules [44] , synthetic modified mRNA [45] , episomes [46] or recombinant proteins [47] . Beyond their cell therapy applications, one major advantage of hiPSCs is to allow the generation of a potentially unlimited library of human cells suitable for HTS (high-throughput screening) and toxicology experiments. Regarding the technical requirements of HTS, in terms of automation, robustness, reproducibility and sensibility, hiPSCs appear to be a real prospect for the pharmaceutical industry. A first proof of concept was obtained in 2009 by Lorenz Studer's group on FD (familial dysautonomia), a fatal peripheral neuropathy caused by a point mutation in the IKBKAP (inhibitor of nuclear factor κB kinase-associated protein) gene [48] . By combining the generation of hiPSCs from patients' fibroblasts and accurate protocols of differentiation, these authors demonstrated a defect in IKBKAP splicing, a decreased rate of neurogenesis, and reduced migration in FD-hiPSC derivatives. Taking advantage of this model, they evaluated the potency of candidate drugs in reversing these phenotypes. This year, another study reported such a strategy for cardiovascular disorders. iPSCs were generated from patients presenting congenital LQTSs (long QT syndromes) to investigate phenotypes of hiPSC-derived cardiomyocytes [49] . The authors demonstrated a pathological prolonged ventricular repolarization of cardiomyocytes derived from LQTShiPSCs and a significant improvement of this phenotype in response to β-blockers, as clinically observed in patients. Because of the absence of any human model of HGPS suitable for HTS, all the compounds investigated in clinical trials (FTIs and ZoPra combination) have up to now been identified through hypothesis-driven strategies, on the basis of the identification of the molecular mechanisms responsible for the defective lamin A precursor maturation, the farnesylation. The recent studies by the groups of Alan Colman [28] and Juan Carlos Izpisúa Belmonte [26, 27] demonstrating that hiPSC derivatives exhibit the phenotypic defects of HGPS have now opened perspectives for screening and censequently discovering new classes of therapeutic compounds, with the possibility of identifying new, effective and safe therapeutics for the children who suffer from this dramatic disease.
Conclusions
Since 2006, considerable progress has been made in understanding the connection between HGPS and normal physiological aging, supporting the idea that the premature aging disease HGPS and normal aging may share a common cellular and molecular basis [50] . The recent discovery of iPSCs offers a glimpse of hope in the development of therapeutic strategies for this syndrome and consequently, because of its similarities, offers the scientific community a tool to decipher the molecular basis of several degenerative disorders related to physiological aging.
